替比夫定对慢性乙型肝炎患者血清sIL-2R及球蛋白水平的影响

摘要

Objective To observe the effect of telbivudine on serum sIL -2R and GLB in patients with chronic hepatitis B(CHB) ,and to investigate the immune regulation of telbivudine s anti -HBV. Methods 30 patients with CHB accepted telbivudine treatment and 30 healthy volunteers were selected. The levels of serum sIL-2R,GLB,ALT,HBV - DNA load were detected before and at 4th weeks, 12th weeks,24th weeks after telbivudine treatment. Results The levels of serum sIL - 2R and GLB were significantly higher compared with the levels of healthy volunteer group ( P ＜ 0.01) . After the treating, the level of serum sIL - 2R in patients raised at 4th week, then decreased at 12th week and then increased at 24th week . The level of serum GLB significantly reduced at 4th week. The levels of ALT and HBV - DNA load fallen as time went on(P ＜ 0. 05). Conclusion Telbivudine not only suppress HBV duplication , but also it may dynamically adjust the levels of sIL - 2R and GLB in patients with CHB and take part in immune function adjustment.%目的 观察替比夫定治疗慢性乙型肝炎(CHB)患者过程中血清可溶性白细胞介素2受体(sIL-2R)和球蛋白(GLB)的水平变化,探讨替比夫定抗乙型肝炎病毒(HBV)的免疫调节作用.方法 选择应用替比夫定治疗的CHB患者30例及健康体检者30例,检测CHB治疗前、治疗后4、12、24周患者血清sIL-2R、GLB、乙型肝炎病毒脱氧核糖核酸(HBV-DNA)及丙氨酸转移酶(ALT)等水平.结果 患者血清sIL-2R和球蛋白水平明显高于正常对照组(P＜0.01)；经替比夫定治疗后,患者血清sIL-2R含量在治疗4周时升高,治疗12周时有所下降,治疗24周时再次升高,且治疗期间均高于健康组基线水平.球蛋白水平从第4周开始随治疗时间延长明显下降,ALT及HBV-DNA水平随治疗时间的延长均逐渐下降(P＜0.05).结论 替比夫定除有效抑制HBV复制外,可动态调节血清sIL-2R及GLB含量,参与机体免疫调节.